IR Notice
Samsung Biologics has been reviewing various shareholder-return policies to boost shareholder value. As result, the board of directors held a board meeting on the 24 January 2022 and reported/disclosed dividend policies as follows.
We will maintain the disclosed dividend policy in 2023*
Disclosure Date : 2022.01.24.
Diclosure Name : Matters Related to Ad Hoc Public Disclosure Obligation (fair Disclosure)
| 1. Details of information | Disclosure title | Establishment of Mid-to Lon-term Dividend Policy to Enhance Shareholder Value |
|---|---|---|
| Summary of ad-cho Public Disclosure |
Background - The Company has established a dividend policy(plan) as a measure for the shareholder returm to enhance shareholder value. Dividend policy(plan) - The Company plans to review whether to carry out cash dividends within 10% of the free cash flow of the given year after 2025. Perido of Duration -The period of duration of this dividend policy(plan) has been set at 3 years in order to improve the predictabiliy of investors. |
|
| Expected ad-hoc public disclosure date & time | - | |
| 2. Details of information release | information providers | IR Team |
| information recipients | investors, Media, etc. | |
| date & time of information release | To be disclosed as needed after this fair disclosure | |
| Titel and place of event held | - | |
| 3. Contact points(department/phone number) | IR Team / 032-455-3114 | |
| 4. Other matters to be factored into investment desisions | ||
|
This dividend policy (plan) has been established to promote the enhancement of shareholder value, and is subject to change depending on the business environment and all related conditions of future investment plans, such as project expansion Free cahs flow, used as the standard for deciding the gross amount of the dividends, is an amount generated through pure project, excluding the amount of external funds and non-recurring items. The dividend for each business year after 2025 will be decided in advance through board approval. This dividend policy (plan) was reported to the board of directors on Jan 24. 2022. |
||
| * Related disclosure | - | |
Thank you
*As of settlement date
Samsung Biologics has been reviewing various shareholder-return policies to boost shareholder value. As result, the board of directors held a board meeting on the 24 January 2022 and reported/disclosed dividend policies as follows.
We will maintain the disclosed dividend policy in 2023*
Disclosure Date : 2022.01.24.
Diclosure Name : Matters Related to Ad Hoc Public Disclosure Obligation (fair Disclosure)
| 1. Details of information | Disclosure title | Establishment of Mid-to Lon-term Dividend Policy to Enhance Shareholder Value |
|---|---|---|
| Summary of ad-cho Public Disclosure |
Background - The Company has established a dividend policy(plan) as a measure for the shareholder returm to enhance shareholder value. Dividend policy(plan) - The Company plans to review whether to carry out cash dividends within 10% of the free cash flow of the given year after 2025. Perido of Duration -The period of duration of this dividend policy(plan) has been set at 3 years in order to improve the predictabiliy of investors. |
|
| Expected ad-hoc public disclosure date & time | - | |
| 2. Details of information release | information providers | IR Team |
| information recipients | investors, Media, etc. | |
| date & time of information release | To be disclosed as needed after this fair disclosure | |
| Titel and place of event held | - | |
| 3. Contact points(department/phone number) | IR Team / 032-455-3114 | |
| 4. Other matters to be factored into investment desisions | ||
|
This dividend policy (plan) has been established to promote the enhancement of shareholder value, and is subject to change depending on the business environment and all related conditions of future investment plans, such as project expansion Free cahs flow, used as the standard for deciding the gross amount of the dividends, is an amount generated through pure project, excluding the amount of external funds and non-recurring items. The dividend for each business year after 2025 will be decided in advance through board approval. This dividend policy (plan) was reported to the board of directors on Jan 24. 2022. |
||
| * Related disclosure | - | |
Thank you
*As of settlement date